Video Insights
Advertisement
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Dr. David Morris discusses the emerging role of copper-based PSMA imaging agents, specifically 64Cu-SAR-bisPSMA.
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Dr. Neal Shore reviews the history of nadofaragene firadenovec in high-risk disease, and the anticipated outcomes of ABLE-32.
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.